GlassScriptPhysician profile
Lisa L Martin
NPI 1821046202
$1,161.45
in general payments reported to CMS, 2019-2025
28 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $93.46 · 2021: $125 · 2022: $191 · 2023: $225 · 2024: $235 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124.59 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $120.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $119.88 | 2020-2024 | Airsupra, Breztri |
| Novo Nordisk INC | $102.70 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $72.60 | 2020-2025 | Trelegy Ellipta, Bexsero, Pediarix |
| Ironshore Pharmaceuticals INC. | $64.76 | 2020-2024 | |
| Ultragenyx Pharmaceutical INC. | $42.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.74 | 2021-2022 | |
| Amgen INC. | $41.31 | 2019 | |
| Axsome Therapeutics, INC. | $40.68 | 2025 | Auvelity |
| Corium, LLC | $30.88 | 2022-2023 | Azstarys |
| Sanofi Pasteur INC. | $30.00 | 2023 | |
| Supernus Pharmaceuticals, INC. | $29.96 | 2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.85 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.42 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $25.73 | 2019 | |
| Kci USA, INC. | $24.95 | 2020 | |
| Abbott Laboratories | $20.63 | 2024 | Freestyle Libre 3 |
| Biogen, INC. | $20.48 | 2023 | Skyclarys |
| Merck Sharp & Dohme LLC | $18.82 | 2023 | Gardasil 9, Vaxneuvance |
| Exact Sciences Corporation | $18.28 | 2023 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $18.04 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.38 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $17.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.39 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.09 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $13.87 | 2020 | |
| Allergan, INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.